Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 6, 1996, Pages 763-772

  Guérin, Maryse ^a,b   Bruckert, Éric ^b   Dolphin, Peter J ^c   Turpin, Gérard ^b   Chapman, M John ^a  

^a Inst Natl de la S et de la R M   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

cholesteryl ester; dyslipoproteinemia; HDL; lipoprotein subspecies; VLDL

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; ISOELECTRIC FOCUSING; MALE; PARTICLE SIZE; PHENOTYPE; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0029941224     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.6.763     Document Type: Article

References (52)

1. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apo B level in subjects with combined hyperlipidemia by reducing the production of apoB containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res. 1990;31:567-582.
2. Goldstein JL, Schrott GG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
3. Janus ED, Nicoll AM, Turner PR, Magill P, Lewis B. Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest. 1980;10:161-172.
4. Kissebah AH, Alfarsi S, Adamo PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in man: normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism. 1981;30:856-868.
5. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia: turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest. 1986;77:663-672.
6. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 1993;34:295-308.
7. McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne RW, Marcel YL. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia: relation to cholesteryl ester protein activity and other lipoprotein variables. Arterioscler Thromb. 1991;11:797-804.
8. Tato F, Vega GL, Tall AR, Grundy SM. Relation between cholesteryl ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vase Biol. 1995;15:112-120.
9. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis. 1993;100:91-102.
10. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low-density lipoproteins are heterogeneous in their interaction with cellular LDL receptor. J Lipid Res. 1991;32:1741-1754.
11. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106:241-253.
12. Caslake MJ, Packard CJ, Gaw A, Murray E, Griffin BA, Vallance BD, Shepherd J. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb. 1993;13:702-711.
13. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
14. De Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 1991;11:298-306.
15. O'Connor P, Feely J, Shepherd J. Lipid lowering drugs. BMJ. 1990;300:667-672.
16. Eisenberg S. Role of fibric acids in the management of hyperlipidemia. Curr Opin Lipidol. 1990;1:34-38.
17. Kissebah AH, Adams PW, Harrigan P, Wynn V. The mechanism of action of clofibrate and tetranicotinoylfructose (bradilan) on the kinetics of plasma free fatty acid and triglyceride transport in type IV and type V hypertriglyceridaemia. Eur J Clin Invest. 1974;4:163-174.
18. Wolfe BM, Kane JP, Havel RJ, Brewster HP. Mechanism of the hypolipidemic effect of clofibrate on postabsorptive man. J Clin Invest. 1973;52:2146-2159.
19. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J din Pharmacol. 1983;25:57-63.
20. Shepherd J, Caslake MJ, Lorimer AR, Vallance BD, Packard CJ. Fenofibrate reduces low-density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis. 1985;5:162-168.
21. Kleinman Y, Oschry Y, Eisenberg S. Abnormal regulation of LDL receptor activity and abnormal cellular metabolism of hypertriglyceridaemic low density lipoprotein: normalization with bezafibrate therapy. Eur J Clin Invest. 1987;17:538-543.
22. Gaw A, Packard CJ, Caslake MJ, Griffin BA, Lindsay GM, Thomson J, Vallance BD, Wosornu D, Shepherd J. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis. 1994;108:137-148.
23. Tikkanen MJ. Fibric acid derivatives. Curr Opin Lipidol. 1992;3:29-33.
24. Blane GF, Bogaievsky Y, Bonnefous F. Fenofibrate: influence on circulating lipids and side-effects in medium and long-term clinical use. In: Fears R, ed. Pharmacological Control of Hyperlipidaemia. Barcelona, Spain: JR Prous Science Publishers; 1986:187-216.
25. Knopp RH, Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Goldberg AC, Grundy SM, Lasser NL, Mellies MJ, Palmer RH, Samuel P, Schonfeld G, Superko HR. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med. 1987;83(suppl 5B):50-59.
26. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronised fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med. 1994;154:441-449.
27. Kornitzer M, Dramaix M, Vandenbroek MD, Everaert L, Gerlinger C. Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. Atherosclerosis. 1994;110(suppl): S49-S54.
28. Guérin M, Dolphin PJ, Chapman MJ. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb. 1994;14:679-685.
29. Guérin M, Dolphin PJ, Talussot C, Gardette J, Berthezene F, Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vase Biol. 1995;15:1359-1368.
30. Lagrost L, Gandjini H, Athias A, Guyard-Dangremont V, Lallemant C, Gambert P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb. 1993;13:815-825.
31. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugation procedure for the isolation of the major lipoprotein classes from human plasma. J Lipid Res. 1981;22:339-358.
32. Chapman MJ, Laplaud PM, Luc G, Forgez P, Bruckert E, Goulinet S, Lagrange D. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 1988;29:442-458.
33. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. 1986;128:417-431.
34. Anderson DW, Nichols AV, Forte TM, Lindgren FT. Particle distribution of human serum high density lipoproteins. Biochim Biophys Acta. 1977;493:55-68.
35. Guérin M, Dolphin PJ, Chapman MJ. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apo B-containing lipoprotein subspecies: identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler Thromb. 1994;14:199-206.
36. Ahnadi CE, Berthezene F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis. 1993;99:219-228.
37. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 1991;88:2059-2066.
38. Guérin M, Bruckert E, Dolphin PJ, Chapman MJ. Absence of CETP-mediated cholesteryl ester mass transfer from HDL to LDL particles is a major feature of combined hyperlipidemia. Eur J Clin Invest. In press.
39. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. J Clin Invest. 1992;90:1290-1295.
40. Kloer HU. Structure and biochemical effects of fenofibrate. Am J Med. 1987;83(suppl 5B):3-8.
41. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994;5:339-349.
42. Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PWF, Castelli WP, Schaefer EJ. LDL particle size distribution: results from the Framingham offspring study. Arterioscler Thromb. 1992;12:1410-1419.
43. McNamara JR, Jenner JL, Li Z, Wilson PWF, Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 1992;12:1284-1290.
44. Luc G, Chapman MJ. Guinea pig low density lipoproteins: structural and metabolic heterogeneity. J Lipid Res. 1988;29:1251-1263.
45. Eisenberg S, Gavish D, Oschry Y, Fairaw M, Deckelbaum RG. Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia: reversal toward normal with bezafibrate treatment. J Clin Invest. 1984;74:470-482.
46. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 1987;83(suppl 5B):9-20.
47. Gottlicher M, Widmark E, Li Q, Gustafsson JA. Fatty acids activate chimera of the clofibric acid-activated receptor and glucocorticoid receptor. Proc Natl Acad Sci U S A. 1992;89:4653-4657.
48. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor retinoid × receptor heterodimers. Proc Natl Acad Sci USA. 1993;90:2160-2164.
49. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipemic action of fibrates. J Clin Invest. 1995;95:705-712.
50. Berthou L, Saladin R, Yaqoob P, Branellec D, Calder P, Fruchart JC, Denèfle P, Auwerx J, Staels B. Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Ear J Biochem. 1995;232:179-187.
51. Staels B, Auwerx J. Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and a-feto-protein as models. Development. 1992;115:1035-1043.
52. Schoonjans K, Staels B, Deed S, Auwerx J. Fibrates and fatty acids induce lipoprotein lipase gene expression via peroxisome proliferator-activated receptor. Circulation. 1995;92(suppl I):I-495. Abstract.